Lenalidomid Grindeks (Lenalidomide)

Lenalidomid Grindeks is used in hematologic oncology to target malignant plasma cells and dysplastic marrow clones.

• Multiple myeloma: helps reduce disease progression and improve survival.
• Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission.
• Mantle cell lymphoma: contributes to disease control when combined with other agents.

• Lenalidomide binds to the cereblon component of the E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in anti‑proliferative, anti‑angiogenic, and immunostimulatory actions that suppress malignant hematopoietic cells.

Lenalidomid Grindeks may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.
• Rash: mild skin eruptions or itching.
• Nausea: feeling of sickness that can affect appetite.
• Low blood counts: reductions in neutrophils, platelets, or red cells.
• Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe infections: opportunistic or bacterial infections requiring hospitalization.
• Secondary primary malignancies: emergence of new cancers.
• Hepatotoxicity: significant liver enzyme elevations.
• Cardiac arrhythmias: irregular heart rhythms.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Lenalidomid Grindeks, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters.

• Pregnancy risk: avoid use in pregnant women; discuss contraception.
• Renal impairment: adjust monitoring for patients with reduced kidney function.
• Hepatic dysfunction: assess liver enzymes prior to therapy.
• Thrombotic risk: consider prophylactic anticoagulation in high‑risk individuals.
• Infection vigilance: monitor for signs of infection and treat promptly.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lenalidomid Grindeks can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may lower lenalidomide exposure.
• Anticoagulants (e.g., warfarin): increased bleeding risk.
• Immunosuppressants (e.g., cyclosporine): heightened infection susceptibility.

Moderate Interactions (Monitor Closely)

• P-glycoprotein inhibitors (e.g., verapamil): may raise plasma levels.
• Other immunomodulatory agents: additive hematologic toxicity.
• Vaccines: live vaccines should be avoided during treatment.